

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 December 2022 (15.12.2022)



(10) International Publication Number
WO 2022/258977 A1

(51) International Patent Classification:

A61K 31/337 (2006.01) A61K 33/243 (2019.01)
A61K 31/5377 (2006.01) A61P 35/00 (2006.01)
A61K 31/555 (2006.01)

(21) International Application Number:

PCT/GB2022/051450

(22) International Filing Date:

09 June 2022 (09.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2108300.1 10 June 2021 (10.06.2021) GB
2108302.7 10 June 2021 (10.06.2021) GB

(71) Applicant: **NATCO PHARMA LIMITED** [IN/IN]; Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana 500034 (IN).

(71) Applicant (for MW only): **SRINIVASAN, Ravi Chandran** [GB/GB]; 80 Turnmill Street, London Greater London EC1M 5QU (GB).

(72) Inventors: **YADLA, Sheshu Babu**; Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana 500034 (IN).

MYNENI, Praveen Chowdary; Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana 500034 (IN). **GOGULA, Venkata Ramana**; Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana 500034 (IN). **NANNA-PANENI, Venkaiah Chowdary**; Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana 500034 (IN).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London Greater London EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER




Figure 1

(57) Abstract: The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The invention also relates to the treatment of head and neck cancer with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof, wherein the treating the head and neck cancer comprises reducing the size of one or more tumours associated with the head and neck cancer.

[Continued on next page]

WO 2022/258977 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*